Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: CTSB (ImmuneEditome ID:1508)

1. Gene summary of enriched editing regions for CTSB

Gene summary

Gene information	Gene symbol	CTSB
	Gene ID	1508
	GeneSynonyms	APPS\|CPSB\|KWE\|RECEUP
	GeneCytomap	8p23.1
	GeneType	protein-coding
	GeneDescription	cathepsin B\|APP secretase\|amyloid precursor protein secretase\|cathepsin B1\|cysteine protease\|epididymis secretory sperm binding protein\|keratolytic winter erythema (Oudtshoorn skin disease)
	GeneModificationdate	20230417
	UniprotID	E9PSG5;P07858;E9PHZ5;A0A024R374;E9PQM1;A0A7I2V4Z9;E9PR21;A0A7I2V2J1;A0A7P0NGZ6;A0A7I2V4S6;E9PCB3;A0A7I2V367;A0A7I2YQK9;A0A7I2V668;A0A7I2V440;A0A7I2V302
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr8:11842752-11844049:-	ENST00000420692.5	ENSG00000164733.19	CTSB	ncRNA_exonic	AluSx1,AluSq2,AluSg	chr8:11842752-11844049:-.alignment
chr8:11849316-11852357:-	ENST00000345125.6	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000353047.9	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000453527.5	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000505496.5	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000524500.4	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000526195.4	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000526645.4	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000527243.4	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000530296.4	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000530640.5	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000531089.4	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000531502.4	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000531551.4	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000533455.4	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000533572.4	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000534149.4	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000534510.4	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11849316-11852357:-	ENST00000534636.4	ENSG00000164733.19	CTSB	exonic	AluSz6,L1MB3,AluSg,(TG)n,MIRb,AluSx1,AluSq	chr8:11849316-11852357:-.alignment
chr8:11854520-11857322:-	ENST00000525076.4	ENSG00000164733.19	CTSB	ncRNA_intronic	AluSx1,AluSz6,AluSx,AluJr,L1M5,AluSg	chr8:11854520-11857322:-.alignment
chr8:11858361-11858612:-	ENST00000525076.4	ENSG00000164733.19	CTSB	ncRNA_intronic	AluJb	chr8:11858361-11858612:-.alignment

Top

2. Tumor-specific enriched editing regions for CTSB

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr8:11842752-11844049:-	BRCA	EER	8.2163e-14
ENSG00000164733.19,CTSB	BRCA	EAG	7.2752e-21
chr8:11842752-11844049:-	COAD	EER	1.1680e-06
ENSG00000164733.19,CTSB	COAD	EAG	5.9478e-07
chr8:11842752-11844049:-	HNSC	EER	4.9356e-15
ENSG00000164733.19,CTSB	HNSC	EAG	5.6387e-17
chr8:11842752-11844049:-	KICH	EER	1.3207e-11
ENSG00000164733.19,CTSB	KICH	EAG	6.3045e-11
chr8:11842752-11844049:-	KIRC	EER	1.2487e-02
ENSG00000164733.19,CTSB	KIRC	EAG	1.2680e-02
chr8:11842752-11844049:-	KIRP	EER	5.6987e-09
ENSG00000164733.19,CTSB	KIRP	EAG	2.3447e-08
chr8:11842752-11844049:-	LIHC	EER	1.1728e-04
ENSG00000164733.19,CTSB	LIHC	EAG	3.1694e-06
chr8:11842752-11844049:-	LUAD	EER	4.3813e-04
ENSG00000164733.19,CTSB	LUAD	EAG	1.8223e-05
ENSG00000164733.19,CTSB	LUSC	EAG	1.6723e-02
chr8:11842752-11844049:-	PRAD	EER	1.5710e-05
ENSG00000164733.19,CTSB	PRAD	EAG	2.2488e-05
chr8:11842752-11844049:-	STAD	EER	8.4313e-05
ENSG00000164733.19,CTSB	STAD	EAG	2.3151e-05
chr8:11842752-11844049:-	THCA	EER	2.5647e-02
chr8:11849316-11852357:-	THCA	EER	3.5428e-03
ENSG00000164733.19,CTSB	THCA	EAG	7.8819e-03
chr8:11842752-11844049:-	UCEC	EER	1.8456e-03
ENSG00000164733.19,CTSB	UCEC	EAG	1.0133e-04

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr8:11842752-11844049:-	BLCA	Path	EER	9.2121e-03	3.0816e-03	0.1501
ENSG00000164733.19,CTSB	BLCA	Path	EAG	2.4113e-02	6.1598e-03	0.1387
ENSG00000164733.19,CTSB	BRCA	Path	EAG	1.2442e-03	1.0819e-02	0.0775
chr8:11842752-11844049:-	BRCA	Path	EER	4.7078e-04	2.3557e-02	0.0689
ENSG00000164733.19,CTSB	KIRC	Path	EAG	1.7577e-02	9.0049e-03	0.1131
ENSG00000164733.19,CTSB	STAD	Path	EAG	1.0214e-02	3.4611e-02	0.1130
chr8:11849316-11852357:-	THCA	Path	EER	6.9685e-03	6.0122e-04	0.1989
ENSG00000164733.19,CTSB	UCEC	Cli	EAG	1.0430e-02	4.2496e-03	0.1224
chr8:11842752-11844049:-	UCEC	Cli	EER	4.3953e-02	1.6550e-02	0.1031

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr8:11842752-11844049:-	PAAD	EER	6.3807e-03	2.7341e-02	7.2745e+03
ENSG00000164733.19,CTSB	PAAD	EAG	4.9452e-03	1.4285e-02	1.0160e+04

Top

3. Enriched editing regions and immune related genes for CTSB

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000197582,GPX1P1

0.3254

2.2275e-02

9.6384e-07

0.4127

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results

Top

4. Enriched editing regions and immune related splicing for CTSB

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr8:11849316-11852357:-

ESCA

EER

ENSG00000166925.4

chr7

100466518:100467600:100467694:100468070

-0.3598

1.2243e-02

1.6467e-06

-0.4368

T_cells_CD4_memory_resting

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr8:11849316-11852357:-

ESCA

EER

ENSG00000198858.5

chr19

901975:902434:902518:902609

-0.3682

6.1420e-03

4.1371e-06

-0.4304

T_cells_CD4_memory_resting

GSVA_HALLMARK_APICAL_SURFACE

More results

Top

5. Enriched editing regions and immune infiltration for CTSB

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr8:11842752-11844049:-	ACC	EER	Macrophages_M2	1.7248e-02	0.2707
ENSG00000164733.19,CTSB	ACC	EAG	Macrophages_M2	1.7685e-02	0.2697
chr8:11842752-11844049:-	BLCA	EER	Macrophages_M1	3.2106e-23	0.4760
ENSG00000164733.19,CTSB	BLCA	EAG	T_cells_CD4_memory_activated	2.5820e-23	0.4758
chr8:11842752-11844049:-	BRCA	EER	T_cells_CD4_memory_activated	2.7095e-15	0.2370
chr8:11849316-11852357:-	BRCA	EER	Plasma_cells	1.3285e-05	0.6432
ENSG00000164733.19,CTSB	BRCA	EAG	T_cells_CD4_memory_activated	3.0557e-20	0.2750
chr8:11842752-11844049:-	CESC	EER	T_cells_CD4_memory_activated	3.2077e-08	0.3140
ENSG00000164733.19,CTSB	CESC	EAG	T_cells_CD4_memory_activated	1.9750e-08	0.3186
chr8:11842752-11844049:-	COAD	EER	Macrophages_M1	1.8073e-05	0.2596
ENSG00000164733.19,CTSB	COAD	EAG	Macrophages_M1	2.3051e-06	0.2824
chr8:11842752-11844049:-	DLBC	EER	T_cells_CD4_memory_resting	1.4128e-03	-0.4479
ENSG00000164733.19,CTSB	DLBC	EAG	Macrophages_M1	1.7896e-04	0.5152
chr8:11842752-11844049:-	ESCA	EER	Macrophages_M2	3.2866e-03	0.2303
chr8:11849316-11852357:-	ESCA	EER	Eosinophils	3.5384e-05	0.3530
chr8:11854520-11857322:-	ESCA	EER	Dendritic_cells_activated	1.3613e-02	0.2401
ENSG00000164733.19,CTSB	ESCA	EAG	Macrophages_M2	1.3663e-03	0.2502
chr8:11842752-11844049:-	GBM	EER	Macrophages_M0	7.0257e-08	-0.4024
ENSG00000164733.19,CTSB	GBM	EAG	Macrophages_M0	9.6509e-09	-0.4258
chr8:11842752-11844049:-	HNSC	EER	Macrophages_M1	1.4278e-10	0.2830
chr8:11849316-11852357:-	HNSC	EER	Dendritic_cells_resting	5.0450e-03	-0.4573
ENSG00000164733.19,CTSB	HNSC	EAG	Macrophages_M1	8.5369e-11	0.2861
chr8:11842752-11844049:-	KICH	EER	Macrophages_M2	1.2088e-02	0.3120
ENSG00000164733.19,CTSB	KICH	EAG	Macrophages_M2	2.5094e-02	0.2799
chr8:11842752-11844049:-	KIRC	EER	T_cells_CD8	1.1360e-05	0.2219
ENSG00000164733.19,CTSB	KIRC	EAG	T_cells_CD8	3.8945e-07	0.2555
chr8:11842752-11844049:-	KIRP	EER	T_cells_CD4_memory_resting	3.1827e-07	-0.2973
ENSG00000164733.19,CTSB	KIRP	EAG	T_cells_CD4_memory_resting	2.5638e-07	-0.2995
chr8:11842752-11844049:-	LAML	EER	NK_cells_activated	5.5140e-06	0.3786
chr8:11849316-11852357:-	LAML	EER	Mast_cells_resting	3.7322e-03	0.3916
chr8:11854520-11857322:-	LAML	EER	Dendritic_cells_resting	2.4612e-05	0.6491
ENSG00000164733.19,CTSB	LAML	EAG	NK_cells_activated	6.6149e-05	0.3318
chr8:11842752-11844049:-	LGG	EER	Macrophages_M2	9.4971e-09	0.2470
ENSG00000164733.19,CTSB	LGG	EAG	Macrophages_M2	1.4759e-08	0.2438
chr8:11842752-11844049:-	LIHC	EER	Macrophages_M0	2.5370e-04	-0.1884
ENSG00000164733.19,CTSB	LIHC	EAG	Macrophages_M0	2.6199e-06	-0.2405
chr8:11842752-11844049:-	LUAD	EER	T_cells_CD4_memory_activated	3.8464e-14	0.3248
chr8:11849316-11852357:-	LUAD	EER	T_cells_gamma_delta	9.0456e-03	0.2883
chr8:11854520-11857322:-	LUAD	EER	T_cells_CD8	2.1478e-03	0.5083
ENSG00000164733.19,CTSB	LUAD	EAG	T_cells_CD4_memory_activated	1.7593e-16	0.3515
chr8:11842752-11844049:-	LUSC	EER	Macrophages_M1	1.5293e-09	0.2667
ENSG00000164733.19,CTSB	LUSC	EAG	T_cells_CD4_memory_activated	1.0333e-09	0.2692
chr8:11842752-11844049:-	MESO	EER	T_cells_CD8	7.2709e-05	0.4238
ENSG00000164733.19,CTSB	MESO	EAG	T_cells_CD8	2.4892e-05	0.4476
chr8:11842752-11844049:-	OV	EER	Macrophages_M1	1.8824e-05	0.2475
chr8:11849316-11852357:-	OV	EER	Eosinophils	3.7114e-03	0.2164
chr8:11854520-11857322:-	OV	EER	Monocytes	1.7841e-02	0.2845
ENSG00000164733.19,CTSB	OV	EAG	Macrophages_M1	1.0746e-06	0.2809
chr8:11842752-11844049:-	PAAD	EER	Macrophages_M1	1.6795e-05	0.3165
ENSG00000164733.19,CTSB	PAAD	EAG	Macrophages_M1	4.7461e-06	0.3353
chr8:11842752-11844049:-	PCPG	EER	T_cells_CD8	2.1166e-05	0.3087
ENSG00000164733.19,CTSB	PCPG	EAG	T_cells_CD8	4.3804e-06	0.3321
chr8:11842752-11844049:-	PRAD	EER	T_cells_regulatory_(Tregs)	3.2013e-07	0.2264
ENSG00000164733.19,CTSB	PRAD	EAG	T_cells_regulatory_(Tregs)	7.4770e-08	0.2379
chr8:11842752-11844049:-	READ	EER	Macrophages_M2	2.5484e-03	0.3078
ENSG00000164733.19,CTSB	READ	EAG	Macrophages_M2	1.4864e-03	0.3232
chr8:11842752-11844049:-	SARC	EER	Macrophages_M1	3.4634e-07	0.3121
ENSG00000164733.19,CTSB	SARC	EAG	Macrophages_M1	4.7936e-08	0.3330
chr8:11842752-11844049:-	SKCM	EER	T_cells_CD8	1.8686e-18	0.3912
chr8:11849316-11852357:-	SKCM	EER	Macrophages_M1	3.5760e-03	0.4167
ENSG00000164733.19,CTSB	SKCM	EAG	T_cells_CD8	1.9335e-20	0.4112
chr8:11842752-11844049:-	STAD	EER	Macrophages_M1	4.1727e-09	0.2991
chr8:11849316-11852357:-	STAD	EER	T_cells_CD8	2.1956e-03	0.1898
chr8:11854520-11857322:-	STAD	EER	T_cells_CD4_memory_activated	1.1477e-05	0.3531
ENSG00000164733.19,CTSB	STAD	EAG	Macrophages_M1	1.3490e-10	0.3254
chr8:11842752-11844049:-	TGCT	EER	Macrophages_M2	6.1684e-11	-0.4931
ENSG00000164733.19,CTSB	TGCT	EAG	Macrophages_M2	4.5525e-15	-0.5743
chr8:11842752-11844049:-	THCA	EER	Macrophages_M2	3.1783e-09	-0.2601
chr8:11849316-11852357:-	THCA	EER	T_cells_regulatory_(Tregs)	5.4530e-03	0.1606
chr8:11854520-11857322:-	THCA	EER	T_cells_CD4_memory_activated	1.0936e-02	0.1610
ENSG00000164733.19,CTSB	THCA	EAG	Macrophages_M2	2.4609e-09	-0.2617
chr8:11842752-11844049:-	THYM	EER	Macrophages_M1	9.0299e-06	0.3960
ENSG00000164733.19,CTSB	THYM	EAG	Macrophages_M1	4.0790e-10	0.5357
chr8:11842752-11844049:-	UCEC	EER	Macrophages_M1	1.6590e-04	0.2825
ENSG00000164733.19,CTSB	UCEC	EAG	Macrophages_M1	1.9389e-05	0.3168
chr8:11842752-11844049:-	UVM	EER	T_cells_CD8	2.7832e-07	0.5372
ENSG00000164733.19,CTSB	UVM	EAG	T_cells_CD8	1.9067e-08	0.5785

Top

6. Enriched editing regions and immune gene sets for CTSB

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events	cancer	Type	E2M_P	Boxplot	CorP	CorR	CorrelationPlot
chr8:11842752-11844049:-	BLCA	EER	3.1123e-05		1.3638e-17	0.4161
ENSG00000164733.19,CTSB	BLCA	EAG	3.6609e-05		3.0841e-18	0.4226
ENSG00000164733.19,CTSB	BRCA	EAG	1.5955e-02		1.9615e-02	0.0709
chr8:11842752-11844049:-	HNSC	EER	2.1820e-05		2.6911e-04	0.1631
ENSG00000164733.19,CTSB	HNSC	EAG	2.3777e-05		2.5159e-04	0.1637
chr8:11842752-11844049:-	KIRP	EER	9.8106e-03		1.4922e-04	0.2228
ENSG00000164733.19,CTSB	KIRP	EAG	1.0465e-02		2.3709e-04	0.2161
ENSG00000164733.19,CTSB	LUSC	EAG	2.5738e-03		1.9348e-02	0.1048

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr8:11842752-11844049:-	BLCA	EER	3.9499e-11	0.3280	3.2350e-06	0.2344	1.8482e-08	0.2814	5.9801e-13	0.3556
ENSG00000164733.19,CTSB	BLCA	EAG	2.8715e-11	0.3293	9.1152e-06	0.2231	5.9169e-09	0.2900	7.9985e-14	0.3671
chr8:11842752-11844049:-	LUAD	EER	3.2891e-07	0.2225	2.8219e-11	0.2875	8.9085e-06	0.1942	8.6998e-03	0.1154
ENSG00000164733.19,CTSB	LUAD	EAG	3.3969e-10	0.2716	1.7409e-14	0.3286	5.5562e-08	0.2361	3.5718e-04	0.1564
chr8:11842752-11844049:-	PAAD	EER	2.9838e-03	0.2214	1.0252e-02	0.1920	1.6826e-02	0.1790	2.2169e-02	0.1714
ENSG00000164733.19,CTSB	PAAD	EAG	9.1358e-04	0.2464	3.0456e-03	0.2209	9.7876e-03	0.1932	6.5863e-03	0.2030
ENSG00000164733.19,CTSB	STAD	EAG	1.2865e-04	0.1975	3.4475e-03	0.1515	1.0219e-03	0.1698	6.7706e-05	0.2053
chr8:11842752-11844049:-	STAD	EER	7.7013e-05	0.2038	1.6116e-03	0.1632	7.7880e-04	0.1737	1.3349e-04	0.1970
ENSG00000164733.19,CTSB	UVM	EAG	2.6418e-03	0.3318	3.4005e-02	0.2374	1.8655e-03	0.3426	1.4019e-04	0.4130

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000164733.19,CTSB	ACC	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	5.0847e-03	0.3162
chr8:11842752-11844049:-	ACC	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	6.5713e-03	0.3072
chr8:11842752-11844049:-	BLCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	3.2450e-38	0.5942
chr8:11849316-11852357:-	BLCA	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EER	3.8259e-02	0.4346
ENSG00000164733.19,CTSB	BLCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	6.1896e-42	0.6162
ENSG00000164733.19,CTSB	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	9.6536e-71	0.5037
chr8:11849316-11852357:-	BRCA	GSVA_HALLMARK_GLYCOLYSIS	EER	3.7454e-03	0.4590
chr8:11842752-11844049:-	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	3.6724e-48	0.4226
ENSG00000164733.19,CTSB	CESC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.0906e-26	0.5672
chr8:11842752-11844049:-	CESC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	1.0680e-23	0.5382
chr8:11849316-11852357:-	CESC	GSVA_HALLMARK_SPERMATOGENESIS	EER	3.2771e-02	-0.3844
chr8:11842752-11844049:-	COAD	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	4.4633e-11	0.3897
ENSG00000164733.19,CTSB	COAD	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	9.8023e-11	0.3799
ENSG00000164733.19,CTSB	DLBC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.2028e-04	0.5267
chr8:11842752-11844049:-	DLBC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	3.8117e-03	0.4099
chr8:11842752-11844049:-	ESCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.5104e-08	0.4278
chr8:11849316-11852357:-	ESCA	GSVA_HALLMARK_DNA_REPAIR	EER	8.6698e-03	0.2285
chr8:11854520-11857322:-	ESCA	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	1.1754e-02	-0.2450
ENSG00000164733.19,CTSB	ESCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	2.7298e-08	0.4208
chr8:11842752-11844049:-	GBM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	3.0676e-08	0.4124
chr8:11849316-11852357:-	GBM	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	2.0047e-02	0.4224
ENSG00000164733.19,CTSB	GBM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	5.2683e-10	0.4572
ENSG00000164733.19,CTSB	HNSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	2.4098e-36	0.5241
chr8:11849316-11852357:-	HNSC	GSVA_HALLMARK_KRAS_SIGNALING_UP	EER	1.4205e-02	0.4053
chr8:11842752-11844049:-	HNSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.7617e-33	0.5056
ENSG00000164733.19,CTSB	KICH	GSVA_HALLMARK_KRAS_SIGNALING_UP	EAG	8.6839e-03	0.3255
chr8:11842752-11844049:-	KICH	GSVA_HALLMARK_KRAS_SIGNALING_UP	EER	2.2267e-02	0.2854
ENSG00000164733.19,CTSB	KIRC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.7365e-15	0.3911
chr8:11842752-11844049:-	KIRC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	4.5454e-12	0.3434
ENSG00000164733.19,CTSB	KIRP	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EAG	2.4545e-15	0.4460
chr8:11842752-11844049:-	KIRP	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	2.4795e-15	0.4460
ENSG00000164733.19,CTSB	LAML	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	9.8786e-03	-0.2182
chr8:11849316-11852357:-	LAML	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	3.2266e-02	-0.2946
chr8:11854520-11857322:-	LAML	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	8.6529e-03	-0.4371
chr8:11842752-11844049:-	LAML	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	3.8861e-03	-0.2460
ENSG00000164733.19,CTSB	LGG	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	4.3503e-33	0.4898
chr8:11842752-11844049:-	LGG	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	7.2222e-26	0.4364
chr8:11842752-11844049:-	LIHC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	1.2009e-09	0.3082
ENSG00000164733.19,CTSB	LIHC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	2.5282e-11	0.3365
chr8:11849316-11852357:-	LUAD	GSVA_HALLMARK_NOTCH_SIGNALING	EER	3.7898e-02	0.2311
chr8:11854520-11857322:-	LUAD	GSVA_HALLMARK_PEROXISOME	EER	9.3748e-05	0.6194
chr8:11842752-11844049:-	LUAD	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	6.2502e-15	0.3342
ENSG00000164733.19,CTSB	LUAD	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.2433e-18	0.3742
chr8:11842752-11844049:-	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.0622e-17	0.3714
ENSG00000164733.19,CTSB	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.0189e-21	0.4110
chr8:11849316-11852357:-	LUSC	GSVA_HALLMARK_MYC_TARGETS_V1	EER	5.4811e-03	0.2423
chr8:11842752-11844049:-	MESO	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	1.7261e-07	0.5392
ENSG00000164733.19,CTSB	MESO	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	2.3774e-08	0.5694
ENSG00000164733.19,CTSB	OV	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.0106e-30	0.6026
chr8:11854520-11857322:-	OV	GSVA_HALLMARK_DNA_REPAIR	EER	1.4807e-02	0.2923
chr8:11842752-11844049:-	OV	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.3124e-25	0.5610
chr8:11849316-11852357:-	OV	GSVA_HALLMARK_DNA_REPAIR	EER	1.4531e-06	0.3520
chr8:11842752-11844049:-	PAAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	3.6976e-10	0.4477
ENSG00000164733.19,CTSB	PAAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	9.3843e-12	0.4822
ENSG00000164733.19,CTSB	PCPG	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	9.6679e-15	0.5316
chr8:11842752-11844049:-	PCPG	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	4.0782e-12	0.4836
chr8:11842752-11844049:-	PRAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.3584e-12	0.3070
ENSG00000164733.19,CTSB	PRAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	6.1796e-13	0.3147
ENSG00000164733.19,CTSB	READ	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	4.6978e-10	0.5878
chr8:11842752-11844049:-	READ	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	1.9535e-09	0.5704
ENSG00000164733.19,CTSB	SARC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	2.7866e-22	0.5572
chr8:11842752-11844049:-	SARC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	5.9507e-20	0.5301
chr8:11849316-11852357:-	SKCM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.7084e-03	0.4453
ENSG00000164733.19,CTSB	SKCM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	2.7601e-26	0.4642
chr8:11842752-11844049:-	SKCM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.1671e-21	0.4235
chr8:11849316-11852357:-	STAD	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EER	7.2320e-04	0.2092
chr8:11854520-11857322:-	STAD	GSVA_HALLMARK_MYC_TARGETS_V1	EER	2.8498e-06	0.3751
chr8:11842752-11844049:-	STAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	4.4400e-25	0.5020
ENSG00000164733.19,CTSB	STAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	8.2193e-31	0.5507
chr8:11842752-11844049:-	TGCT	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	3.4978e-07	0.3944
ENSG00000164733.19,CTSB	TGCT	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	2.2511e-10	0.4802
ENSG00000164733.19,CTSB	THCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.1733e-22	0.4173
chr8:11842752-11844049:-	THCA	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	2.1139e-23	0.4243
chr8:11849316-11852357:-	THCA	GSVA_HALLMARK_GLYCOLYSIS	EER	3.4946e-05	0.2373
chr8:11842752-11844049:-	THYM	GSVA_HALLMARK_G2M_CHECKPOINT	EER	4.5161e-04	-0.3179
ENSG00000164733.19,CTSB	THYM	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	4.2681e-05	0.3674
ENSG00000164733.19,CTSB	UCEC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	4.1701e-06	0.3399
chr8:11842752-11844049:-	UCEC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	1.4797e-05	0.3228
chr8:11842752-11844049:-	UCS	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	8.4705e-03	0.3486
ENSG00000164733.19,CTSB	UCS	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	2.9485e-03	0.3902
ENSG00000164733.19,CTSB	UVM	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.0615e-13	0.7139
chr8:11842752-11844049:-	UVM	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	6.8282e-12	0.6746

Top

7. Enriched editing regions and drugs for CTSB

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr8:11842752-11844049:-	ACC	Bicalutamide	EER	2.0726e-02	-0.2632
ENSG00000164733.19,CTSB	ACC	JNK.9L	EAG	1.9021e-02	-0.2668
ENSG00000164733.19,CTSB	BLCA	CGP.60474	EAG	1.0825e-23	-0.4794
chr8:11849316-11852357:-	BLCA	GSK.650394	EER	7.0903e-03	0.5456
chr8:11842752-11844049:-	BLCA	CGP.60474	EER	6.7034e-23	-0.4729
ENSG00000164733.19,CTSB	BRCA	CGP.082996	EAG	9.0200e-17	-0.2490
chr8:11842752-11844049:-	BRCA	Cisplatin	EER	2.5697e-13	-0.2198
chr8:11849316-11852357:-	BRCA	AICAR	EER	1.0140e-03	0.5121
ENSG00000164733.19,CTSB	CESC	CI.1040	EAG	1.0667e-16	-0.4566
chr8:11842752-11844049:-	CESC	CI.1040	EER	1.9929e-14	-0.4246
ENSG00000164733.19,CTSB	CHOL	AZD6482	EAG	2.1289e-02	-0.3936
chr8:11842752-11844049:-	CHOL	JNJ.26854165	EER	3.0088e-02	-0.3724
chr8:11842752-11844049:-	COAD	Cisplatin	EER	1.3943e-08	-0.3391
ENSG00000164733.19,CTSB	COAD	Gefitinib	EAG	3.9490e-10	-0.3683
ENSG00000164733.19,CTSB	DLBC	Cisplatin	EAG	8.2558e-03	-0.3770
chr8:11842752-11844049:-	DLBC	AZD6244	EER	2.5057e-02	-0.3232
chr8:11854520-11857322:-	ESCA	GSK.650394	EER	2.1985e-02	-0.2234
ENSG00000164733.19,CTSB	ESCA	CGP.60474	EAG	1.7129e-04	-0.2920
chr8:11849316-11852357:-	ESCA	JW.7.52.1	EER	7.9641e-04	-0.2895
chr8:11842752-11844049:-	ESCA	CGP.60474	EER	1.7827e-03	-0.2444
chr8:11842752-11844049:-	GBM	CEP.701	EER	4.1498e-05	0.3116
chr8:11849316-11852357:-	GBM	AKT.inhibitor.VIII	EER	5.0012e-03	0.4990
ENSG00000164733.19,CTSB	GBM	Axitinib	EAG	3.4574e-06	0.3504
chr8:11842752-11844049:-	HNSC	FH535	EER	1.7483e-11	0.2962
ENSG00000164733.19,CTSB	HNSC	FH535	EAG	1.4376e-11	0.2971
chr8:11849316-11852357:-	HNSC	BMS.536924	EER	9.6029e-04	-0.5270
ENSG00000164733.19,CTSB	KICH	A.443654	EAG	4.2379e-03	0.3529
chr8:11842752-11844049:-	KICH	A.443654	EER	7.1573e-03	0.3331
chr8:11842752-11844049:-	KIRC	Camptothecin	EER	6.3929e-07	-0.2508
ENSG00000164733.19,CTSB	KIRC	Camptothecin	EAG	1.1127e-08	-0.2863
chr8:11849316-11852357:-	KIRP	GW843682X	EER	2.5497e-04	-0.7169
ENSG00000164733.19,CTSB	KIRP	CMK	EAG	1.8327e-16	0.4618
chr8:11842752-11844049:-	KIRP	CMK	EER	1.9378e-17	0.4749
ENSG00000164733.19,CTSB	LAML	CCT018159	EAG	1.7364e-02	0.2015
chr8:11854520-11857322:-	LAML	BIBW2992	EER	8.3969e-05	-0.6152
chr8:11849316-11852357:-	LAML	Etoposide	EER	1.9739e-03	-0.4155
chr8:11842752-11844049:-	LAML	GSK.650394	EER	2.7971e-02	-0.1885
chr8:11842752-11844049:-	LGG	Axitinib	EER	1.0507e-28	0.4585
ENSG00000164733.19,CTSB	LGG	Axitinib	EAG	1.2483e-32	0.4867
chr8:11842752-11844049:-	LIHC	BMS.754807	EER	4.5927e-09	0.2984
ENSG00000164733.19,CTSB	LIHC	BMS.754807	EAG	3.2168e-13	0.3662
chr8:11849316-11852357:-	LUAD	ABT.263	EER	6.6160e-03	0.2994
chr8:11842752-11844049:-	LUAD	Gemcitabine	EER	9.5154e-15	-0.3321
chr8:11854520-11857322:-	LUAD	Embelin	EER	4.3233e-03	0.4772
ENSG00000164733.19,CTSB	LUAD	Gemcitabine	EAG	3.6943e-15	-0.3366
chr8:11849316-11852357:-	LUSC	Methotrexate	EER	1.3207e-02	-0.2177
chr8:11842752-11844049:-	LUSC	Gemcitabine	EER	5.8688e-07	-0.2218
ENSG00000164733.19,CTSB	LUSC	Gemcitabine	EAG	7.6649e-07	-0.2194
ENSG00000164733.19,CTSB	MESO	Gemcitabine	EAG	4.9543e-03	-0.3075
chr8:11842752-11844049:-	MESO	Cisplatin	EER	2.7664e-03	-0.3264
ENSG00000164733.19,CTSB	OV	Cytarabine	EAG	4.6959e-09	0.3343
chr8:11849316-11852357:-	OV	Lenalidomide	EER	5.5854e-03	0.2075
chr8:11842752-11844049:-	OV	Cytarabine	EER	1.8009e-08	0.3220
chr8:11842752-11844049:-	PAAD	EHT.1864	EER	1.3140e-02	0.1888
ENSG00000164733.19,CTSB	PAAD	EHT.1864	EAG	7.8949e-03	0.2019
ENSG00000164733.19,CTSB	PCPG	BI.2536	EAG	4.7535e-06	0.3309
chr8:11842752-11844049:-	PCPG	BI.2536	EER	4.6533e-05	0.2963
chr8:11842752-11844049:-	PRAD	Bicalutamide	EER	6.4214e-11	0.2870
ENSG00000164733.19,CTSB	PRAD	JNK.Inhibitor.VIII	EAG	3.9010e-14	-0.3299
ENSG00000164733.19,CTSB	READ	CGP.60474	EAG	2.0632e-05	-0.4240
chr8:11842752-11844049:-	READ	AP.24534	EER	1.3565e-04	-0.3835
ENSG00000164733.19,CTSB	SARC	AP.24534	EAG	1.7674e-12	-0.4220
chr8:11842752-11844049:-	SARC	AP.24534	EER	1.6629e-11	-0.4046
ENSG00000164733.19,CTSB	SKCM	JNK.9L	EAG	6.9939e-11	-0.2961
chr8:11842752-11844049:-	SKCM	JNK.9L	EER	3.7468e-10	-0.2852
chr8:11849316-11852357:-	SKCM	CCT007093	EER	2.9447e-02	-0.3179
chr8:11842752-11844049:-	STAD	Gemcitabine	EER	9.6760e-09	-0.2923
ENSG00000164733.19,CTSB	STAD	Gemcitabine	EAG	1.4789e-09	-0.3073
chr8:11854520-11857322:-	STAD	Gemcitabine	EER	1.9571e-04	-0.3025
ENSG00000164733.19,CTSB	TGCT	ABT.888	EAG	7.9675e-12	-0.5125
chr8:11842752-11844049:-	TGCT	BMS.708163	EER	3.0289e-09	-0.4525
ENSG00000164733.19,CTSB	THCA	AICAR	EAG	2.0625e-19	-0.3866
chr8:11842752-11844049:-	THCA	CI.1040	EER	1.6364e-18	-0.3778
chr8:11854520-11857322:-	THCA	Gemcitabine	EER	6.4763e-04	-0.2147
chr8:11849316-11852357:-	THCA	CCT007093	EER	2.0083e-13	0.4087
chr8:11842752-11844049:-	THYM	Doxorubicin	EER	9.5310e-05	0.3514
ENSG00000164733.19,CTSB	THYM	Doxorubicin	EAG	2.3702e-07	0.4543
ENSG00000164733.19,CTSB	UCEC	Cisplatin	EAG	1.0070e-05	-0.3269
chr8:11842752-11844049:-	UCEC	Cisplatin	EER	2.8483e-05	-0.3125
chr8:11842752-11844049:-	UCS	CGP.60474	EER	1.2488e-02	-0.3318
ENSG00000164733.19,CTSB	UCS	CGP.60474	EAG	6.2590e-03	-0.3611
ENSG00000164733.19,CTSB	UVM	GSK.650394	EAG	3.4199e-08	0.5700
chr8:11842752-11844049:-	UVM	Epothilone.B	EER	5.4929e-08	0.5629

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType